Does Epclusa have a high therapeutic rate as a specific drug?

Epclusa is an oral anti-HCV targeted drug developed by Gilead. Its scientific name is Sofosbuvir/Velpatasvir combination tablet. It is widely regarded as a specific drug for the treatment of hepatitis C and is suitable for all six genotypes of HCV infection, so it has the reputation of "genotype-wide treatment regimen". The advent of Gen3 has greatly simplified the process of hepatitis C treatment, eliminating the need to choose a plan based on genotype, making treatment more standardized and popular.

Judging from clinical data, Jisandai’s cure rate is very high. Multiple large-scale international clinical studies have shown that after 12weeks of treatment with the third-generation treatment, the virological cure rate (SVR12, or sustained virological response) of hepatitis C patients can reach 95% or more. For certain genotypes or patients with liver cirrhosis, the cure rate is also close to or exceeding 90%, demonstrating its broad-spectrum and potent antiviral ability. Especially in patients who have not received antiviral treatment or who do not have severe liver function impairment, the therapeutic effect of Jisanda is particularly significant.

Another major advantage of Jisandai is that it is well tolerated and has mild side effects. Most patients will not experience serious discomfort during the entire course of treatment. Common side effects include mild headache, fatigue, nausea, etc., which generally do not affect the progress of treatment. Compared with traditional interferon + ribavirin therapy, GISID does not require injections, has a shorter course of treatment, and has milder side effects. Therefore, patients have higher compliance and help achieve a higher cure rate.

In general, Jisandai is an important breakthrough in the field of hepatitis C treatment. With its all-genotype indications, high virus clearance rate and good safety, it is regarded as a "specific drug" for hepatitis C globally. For patients who hope to completely cure hepatitis C, Jisandai is currently one of the most trustworthy treatment options. Patients should undergo a comprehensive evaluation before receiving treatment with Jisandai, and the doctor will formulate an appropriate treatment cycle and plan based on the condition to ensure the desired effect.

Reference: https://www.epclusa.com/